Waddell & Reed Financial’s Aratana Therapeutics, Inc. PETX Stock Holding History

Waddell & Reed Financial’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-80,000	Closed	-$506K	–	636
2016 Q2	$506K	Sell	80,000 -121,500	-60%	-$781K	﹤0.01%	575
2016 Q1	$1.11M	Sell	201,500 -48,500	-19%	-$182K	﹤0.01%	584
2015 Q4	$1.4M	Sell	250,000 -918,500	-79%	-$6.07M	﹤0.01%	605
2015 Q3	$9.88M	Buy	1,168,500 +1,003,500	+608%	+$17M	0.02%	405
2015 Q2	$2.5M	Sell	165,000 -40,000	-20%	-$578K	﹤0.01%	547
2015 Q1	$3.28M	Buy	205,000 +5,000	+3%	+$89K	﹤0.01%	525
2014 Q4	$3.56M	Sell	200,000 -200,600	-50%	-$2.5M	﹤0.01%	509
2014 Q3	$4.02M	Sell	400,600 -10,000	-2%	-$121K	0.01%	506
2014 Q2	$6.41M	Sell	410,600 -45,600	-10%	-$646K	0.01%	485
2014 Q1	$8.47M	Buy	+456,200	New	+$9.14M	0.01%	455

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Waddell & Reed Financial's PETX Position: Q3 2016 in Review

Waddell & Reed Financial sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 80,000 shares — an estimated $506K sold.

Waddell & Reed Financial first reported a position in PETX in Q1 2014 and held it in 10 quarters. The position peaked at $9.88M in Q3 2015. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

Waddell & Reed Financial reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Waddell & Reed Financial sold 80,000 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $506K.
Waddell & Reed Financial first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
Waddell & Reed Financial's Aratana Therapeutics, Inc. position peaked at $9.88M in Q3 2015.
128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Waddell & Reed Financial's 13F filing for Q3 2016, filed 14 Nov 2016.